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Background: Tuberous Sclerosis Complex (TSC) is a multi-system genetic disorder charac-
terised by the development of benign growths and diverse clinical manifestations, varying
in severity, age at onset and with high clinical burden.
Aims: This longitudinal study aims to describe the broad spectrum of clinical manifestation
profiles in a large, representative cohort of TSC patients in the UK in order to better un-
derstand disease complexity.
Methods: TSC patients in the Clinical Practice Research Datalink (CPRD) and linked Hospital
Episodes Statistics (CPRD-HES) were retrospectively identified between 1987 and 2013.
Available history was extracted for each patient and clinical diagnosis, procedure and
medication records reviewed. A random selection of patients from the CPRD-HES was used
as a Comparator cohort.
Results: Three hundred and thirty-four TSC patients with a mean (SD) age of 30.3
(18.6) years were identified (53% female). TSC was diagnosed at mean age 3.2 (4.2) years.
Epilepsy and psychiatric manifestations were reported frequently in paediatric (77%
and 55%, respectively) and adult patients (66% and 68%, respectively). The prevalencem, chris.kingswood@bsuh.nhs.uk (C. Kingswood).
y Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
).
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The majority of paediatric (46%) and adult TSC patients (62%) developed clinical manifes-
tations affecting at least three organ systems and forty-nine distinctive organ system
manifestation profiles were identified.
Conclusions: TSC patients present with multiple and complex clinical manifestations and
profiles that necessitate the co-ordinated action of a multidisciplinary team in order to
improve the quality and efficiency of care.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberous sclerosis complex (TSC) is a rare genetic disease
associated with the development of non-malignant tumours
throughout the body. Mutations in the TSC1 and TSC2 genes,
which encode the proteins hamartin and tuberin,1e3 are
detected in approximately 85e90% of TSC cases.4e10 The ma-
jority of TSC cases occur sporadically, with a family history
found in only 30% of patients.1,6,11e13 The incidence of TSC is
estimated to be between 1/6000 and 1/10,000 live births and
the population prevalence is estimated to be 1/20,000.14,15
Approximately 1 in 12,000e14,000 children under 10 years of
age have TSC according to population-based studies in the
UK.14,16 Worldwide, TSC is thought to affect 1 to 2 million
individuals.
The clinical presentation of TSC is highly variable be-
tween individuals and typically varies throughout the life-
time of a single patient, both factors making for a highly
heterogeneous presentation of the disease when assessing
the patient population cross-sectionally.13,17 The diverse
timing of the onset of manifestations and the symptoms and
signs they cause adds to the complexity of the condition. The
central nervous system (CNS), dermatological, renal, respi-
ratory and circulatory organ systems are most commonly
affected, although few of these manifestations are specific to
TSC.13,18,19 Infantile spasms are usually the first detected
manifestations. Neurodevelopmental and dermatological
manifestations also typically present early in life, though are
frequently misdiagnosed. Clinical complications from renal
manifestations, on the other hand, are often first observed in
adolescence or adulthood; although renal involvement can
be demonstrated much earlier (age 3e5) and presumably
starts even earlier on the microscopic scale. Respiratory
system involvement, almost exclusively symptomatic in fe-
male TSC patients, typically presents in adults. Ocular and
bone abnormalities have been commonly reported but are
not diagnostic.10,18 Other organ systems including the
gastrointestinal, hepatic, auditory and endocrine systems
are less commonly affected by TSC.13,18e20
The diagnosis of TSC can be challenging due to the het-
erogeneous presentation of the disease. Based on the 2012
International TSC Consensus Group guidelines,18,21 clinical
features of TSC continue to be the principal means of diag-
nosis with the presence of two major features or one major
plus two minor features necessary for a definitive diagnosis.
In addition, identification of a pathogenic TSC1 or TSC2
mutation by genetic testing is considered an independent
diagnostic criterion, although in 10e15% of clinically-affected patients, current testing is not able to identify
such a mutation.18
Beyond diagnosis, TSC presents the clinical community
with challenges in delivering adequate care given the number
of organ systems affected by the disease and the age-
dependent nature of manifestations. Such challenges were
addressed by the consensus group for surveillance and man-
agement.21 Recommendations from this group highlight the
need for a holistic and coordinated management approach in
order to deliver efficient and effective care for TSC patients
throughout their lifetime.
Barriers to improving thequality andcoordinationof care in
TSC are compounded by the lack of long-term studies that
collate information across the broad spectrum of manifesta-
tions, analyse the combinations of organsystems involvedand
document the age of onset and progression of clinical features.
Previous studies of TSC have focused on defined subsets of the
disease, typically in small patient populations, and usually
addressing a particular manifestation or organ system. The
current study uses a longitudinal database to enhance under-
standing of the natural history of TSC in a large cohort of
paediatric and adult patients in the community setting in the
UK. The study describes the broad spectrumand complexity of
patient manifestation profiles, including the age-related
emergence of clinical features, with the aim of supporting cli-
nicians' diagnosis, surveillance and management of TSC.
By providing a long-term picture of TSC in the community
in the UK, this study aims to improve diagnosis, surveillance
and management of TSC, and to aid the development of care
pathways to improve long-term health outcomes for patients.2. Methods
2.1. Study design and data source
The study was a retrospective cohort analysis of UK patient
data from the Clinical Practice Research Datalink (CPRD)
linked (via patient National Health Service [NHS] number) to
secondary care data from the Hospital Episodes Statistics
(CPRD-HES) database and the Office of National Statistics
(ONS) mortality register.
The CPRD is an electronic medical record database with
longitudinal data available from 1987. Currently, it includes
approximately 6 million active patients (approximately 15.5
million patients in total) from over 680 primary care practices
throughout the UK, representing approximately 8% coverage
of the general UK population.22 The CPRD consists of a number
Table 1 e Medical inventory of TSC organ system codes
(MedITOSC).
Organ system Manifestations
Central nervous
system (CNS)a
 Brain (Structural): Brain neoplasms
(including subependymal giant cell as-
trocytoma [SEGA]), hydrocephalus, ce-
rebral cyst, stroke/transient ischaemic
attack (TIA)
 Nervous System: Epilepsy (including
convulsions and any fit; excluding
febrile convulsions), ataxia/hemiplegia
 Psychiatric: Learning/intellectual
disability, autism spectrum disorders,
sleep disorder, hallucinations, behav-
ioural disorder, speech and language
disorders, attention deficit hyperactivity
disorder (ADHD), bipolar disorder,
depression, anxiety, psychosis/schizo-
phrenia, dysphasia/aphasia, anorexia
Kidney and
urinary tracta
 Polycystic kidney disease, kidney cyst,
chronic kidney disease stage 3e5, kid-
ney neoplasms (including angiomyoli-
pomas), haematuria
Circulatory
systema
 Cardiac rhabdomyoma, hypertension,
arrhythmia, myocardial infarction/
angina, cerebral/cardiac aneurysmb
Dermatologicala  Angiofibroma, benign skin neoplasms,
naevus, acne vulgaris/rosacea, cafe au
lait spots, rhinophyma, nail manifesta-
tions, skin tag, impetigo, other skin-
related lesions, lymphoedema
Respiratorya  Lymphangioleiomyomatosis (LAM)c
Ocular  Visual impairment (including partial
sight, poor visual acuity, registered
blind, unspecified visual loss, loss of
vision, deteriorating vision)
gastrointestinal
system
 Benign neoplasms/polyp of colon
Endocrine
system
 Hyperthyroidism, hypothyroidism
a Primary organ system.
b Hypomelanotic lesions were not captured by coding.
c Suspected cases of LAM only due to unavailability of specific LAM
diagnosis codes in CPRD-HES.
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mographics, clinical diagnoses, consultations, co-morbidities,
prescription medications, routine tests and specialist re-
ferrals.23,24 Diagnoses are assigned by clinicians and recorded
using the Oxford Medical Information System classification
and Read Clinical Terms. Prescription medications are coded
according to the CPRD product code. All data files within the
CPRD (except the free-text notes) were reviewed and evalu-
ated for inclusion in the current study.
The HES database provides information on inpatient care
(including those patients admitted through the accident and
emergency department) delivered by NHS hospitals in En-
gland, with data linked to CPRD available from April 1997 to
March 2012 (approximately 50% of GP practices in England
are linked to HES data). Data including basic demographics,
clinical diagnoses (recorded using World Health Organiza-
tion International Classification of Disease [ICD]-10 codes),
procedures (recorded using Office of Population Censuses
and Surveys [OPCS] Classification of Interventions and Pro-
cedures version 4]) and administrative information (date of
admission) are captured in HES. Outpatient attendance data
is also captured in HES and was available from April 2003 to
March 2012. ONS is part of the Executive Office of the UK
Statistics Authority and collects, compiles, analyses and
disseminates a range of economic, social and demographic
statistics relating to the UK. Linked ONS mortality data was
available from January 1998 to January 2012.
The CPRD has been well validated and has previously been
used to support the design and implementation of epidemio-
logical cohort studies.23e28
2.2. Patient population
Subjects were identified based on a diagnosis of TSC recorded
in the CRPD-HES (Read codes, PK5..00, PK5..12; ICD-10 code,
Q85.1) from 1st January, 1987 to 30th June, 2013 (the latest date
at which data was available at the time of extraction). All
patientswith a record of TSC in the CPRD forwhom linkedHES
data were available were included in the study, regardless of
the length of history available for each patient. Patients with
an incorrectly coded TSC diagnosis, as determined by clinician
review, were excluded from the study.
All available history was extracted for each TSC patient
identified, including demographic (gender and age) and clin-
ical data (diagnoses, symptoms, prescription medication, in-
vestigations and procedures, including surgical interventions
and imaging tests).
2.3. Data categorisation
Data were aggregated for each patient to construct (to the
extent possible) a comprehensive medical history. To
accommodate the volume and complexity of records, each
diagnosis, procedure and prescription medication was
reviewed by a panel of clinical experts to determine the extent
to which they were related to TSC. Records were then grouped
by affected organ system in a TSC clinical code library d the
Medical Inventory of TSC Organ System Codes (MedITOSC) d
whichwas used to systematically assess the population (Table
1). Seven primary manifestation categories (hereafter referredto as ‘primary organ systems’) affected by TSCwere identified;
brain (structural), nervous system, psychiatric, kidney and
urinary tract, circulatory system, dermatological and
respiratory.
The relationship of manifestations with TSC was further
categorised based on having: i) a high degree of certainty of
being directly related to TSC (TSC-related); or ii) a likelihood of
association with TSC (TSC-associated), either directly or
indirectly. Data records considered by the clinical expert panel
to be unrelated to TSC were excluded from the analyses.
2.4. Data analyses
Analyses were performed on the entire ‘TSC’ cohort and on
the TSC sub-cohort for whom records were available from
birth (‘TSC Birth’ cohort). A random sample of 100,000 patients
from the general CPRD population, with linked HES data, was
used as a ‘Comparator’ cohort for analyses. Demographic
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of the last available record for each patient), are reported
consistently for TSC and Comparator cohorts.
The frequency of TSC-related and TSC-associated clinical
manifestations in the TSC cohort was analysed by individual
manifestation and by organ system, and further stratified by
paediatric (<18 years) and adult (18 years) patients. The
frequency of select clinical manifestations was also compared
with the Comparator cohort by age intervals in order to ac-
count for the development of some manifestations later in
adulthood.
Data are presented as summary statistics where contin-
uous variables are presented asmean, standard deviation (SD)
and median values and categorical variables are reported as
frequencies and percentages along with 95% confidence in-
tervals, where appropriate. Statistical analysis was performed
using SAS® version 9.2.
2.5. Ethics
Independent Scientific Advisory Committee (ISAC) for Medi-
cine and Healthcare Products Regulatory Agency (MHRA)
Database Research approval was obtained for this study on
2nd September 2013 (Protocol 13_146).3. Results
3.1. Patient demographics
A total of 334 patients with a TSC diagnosis were identified in
the CPRD-HES database (TSC cohort). The TSC cohort had a
mean (SD) available history of 17.4 (6.4) years (median, 18.7
years), a slightly higher proportion of females (53%) and a
mean age of 30.3 (18.6) years, based on the patients' last
available record. The age distribution of the TSC cohort is
shown in Fig. 1. The majority (65%) of patients were under the
age of 35 years; only 11% of patients were over 55 years of age.
Demographics in the TSC cohort were compared with
those in the Comparator cohort in order to establish any dif-
ferences with the general CPRD population. Mean (SD) avail-
able follow-up in the Comparator cohort was similar to that
observed in the TSC cohort (15.7 [7.2] years; median, 16.8
years) aswas the gender distribution (57% female). In contrast,
the mean age of patients in the Comparator cohort was
markedly higher (43.1 [25.6] years) versus the TSC cohort, with
a substantially greater proportion of patients (42%) over the
age of 55 years (Fig. 1).
3.2. Prevalence of TSC clinical manifestations by
primary organ system
As clinical manifestations are known to develop at different
times throughout the disease course, the prevalence of TSC-
related and TSC-associated manifestations by primary organ
system were analysed separately for paediatric and adult pa-
tients in the TSC cohort (Fig. 2). Over three quarters of paedi-
atric patients developed nervous system manifestations
(predominantly epilepsy) and one in every two patients
developed a psychiatric manifestation. Manifestationsimpacting the circulatory system were also prevalent in the
paediatric TSC cohort, developing in nearly one quarter (23%)
of patients, while 13% were reported to show structural
manifestations of the brain excluding tubers. The prevalence
of nervous system and psychiatric manifestations remained
high in the adult TSC cohort (66% and 68%, respectively).
Kidney and urinary tract manifestations were primarily re-
ported later in adult life (34% vs. 4%, paediatric TSC cohort).
Dermatological manifestations were prevalent in themajority
of the paediatric and adult TSC cohort (69% and 81%, respec-
tively). Respiratorymanifestations were identified in less than
2% of adult TSC patients.
3.3. Comparison of prevalence of clinical manifestations
in the TSC cohort versus the comparator cohort
The prevalence of TSC-related and TSC-associated manifes-
tations was examined separately in the TSC cohort for pae-
diatric and adult patients (Tables 2A and 2B) and compared
with the Comparator cohort (Table 2A). For the majority of
manifestations compared, prevalence wasmarkedly higher in
the TSC cohort than in the Comparator cohort, with depres-
sion the only exception (occurring at similar frequencies at
each age interval). In comparisonwith the Comparator cohort,
paediatric TSC patients were shown to have a higher preva-
lence of brain neoplasms (11% vs. 0%), epilepsy (77% vs. 3%),
autism spectrum disorders (16% vs. 1%), attention deficit hy-
peractivity disorder (ADHD; 7% vs. 1%), learning/intellectual
disability (34% vs. 1%) and cardiac rhabdomyomas (19% vs.
0%). In the TSC cohort, the prevalence of kidney neoplasms
was also markedly higher than that observed in the Compar-
ator cohort, with the highest prevalence observed at 56e65
years (21% vs. 0%). Chronic kidney disease (CKD stage 3e5)
was also identified more frequently in the TSC cohort
compared with the Comparator cohort at all age intervals and
peaked at >65 years of age (42% vs. 23%). A higher prevalence
of stroke/transient ischaemic attack (TIA) was observed in the
TSC cohort compared with the Comparator cohort (Table 2A).
The prevalence of visual impairment and hypothyroidism/
hyperthyroidism, less commonly reported clinical manifes-
tations,18,29 were also markedly higher in the TSC cohort than
in the Comparator cohort at all age intervals (Table 2A).
Prevalence of visual impairment peaked at 46e55 years (7% vs.
1%), while diagnosis of hypothyroidism/hyperthyroidism was
most prevalent at ages 56e65 years (37% vs. 7%). Furthermore,
a higher prevalence of impetigo and lymphoedema was
observed in adult TSC patients relative to the Comparator
cohort (Table 2A).
3.4. Age at first diagnosis of TSC manifestations
To gain insight intowhen TSC clinicalmanifestations develop,
age at first diagnosis of select manifestations (n  5) by pri-
mary organ system was reported in the TSC Birth cohort
(Fig. 3). Cardiac rhabdomyomas followed by epilepsy were the
earliest detected manifestations, with the former commonly
diagnosed within the first year of life (mean [SD]; 0.8 (1.4) and
2.1 [3.4] years of age, respectively). On average, psychiatric
manifestations were also initially diagnosed at a relatively
young age (<10 years), including sleep disorders, speech and
Fig. 1 e Age distribution by gender of the TSC cohort (n ¼ 334) versus the Comparator cohort (n ¼ 100,000). Age defined at
the point of the last available record for each patient.
Fig. 2 e Comparison of prevalence (95% confidence intervals) of clinical manifestations (TSC-related and TSC-associated) by
primary organ system in paediatric (n¼ 94) versus adult (n¼ 240) patients in the TSC cohort. Age defined at the point of the
last available record for each patient.
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Table 2A e Prevalence of select clinical manifestations in the TSC cohort versus the Comparator cohort.
TSC clinical manifestations <18 yrsa
TSC n ¼ 94
Comp. n ¼ 18,321
18e25 yrsa
TSC n ¼ 59
Comp. n ¼ 8326
26e35 yrsa
TSC n ¼ 62
Comp. n ¼ 15,800
36e45 yrsa
TSC n ¼ 51
Comp. n ¼ 14,733
46e55 yrsa
TSC n ¼ 30
Comp. n ¼ 10,834
56e65 yrsa
TSC n ¼ 19
Comp. n ¼ 9051
>65 yrsa
TSC n ¼ 19
Comp. n ¼ 22,935
n %
(95% CI)
n %
(95% CI)
n %
(95% CI)
n %
(95% CI)
n %
(95% CI)
n %
(95% CI)
n %
(95% CI)
Brain (Structural)
Brain Neoplasms
(inc. SEGA)b
TSC 10 10.6(5.2e18.7) 12 20.3(11.032.8) 9 14.5(6.9e25.8) 4 7.8(2.2e18.9) 0 e 2 10.5(1.3e33.1) 0 e
Comp. 8 0.0(0.0e0.1) 9 0.1(0.0e0.2) 12 0.1(0.0e0.1) 26 0.2(0.1e0.2) 32 0.3(0.2e0.4) 32 0.4(0.2e0.5) 71 0.3(0.2e0.4)
Cerebral Cyst TSC 0 e 2 3.4(0.4e11.7) 1 1.6(0.0e8.7) 1 2.0(0.1e10.5) 0 e 0 e 0 e
Comp. 6 0.0(0.0e0.1) 4 0.0(0.0e0.1) 8 0.1(0.0e0.1) 8 0.1(0.0e0.1) 8 0.1(0.0e0.1) 6 0.1(0.0e0.1) 14 0.1(0.0e0.1)
Stroke/TIAb TSC 1 1.1(0.0e5.8) 0 e 0 e 3 5.9(1.2e16.2) 2 6.7(0.8e22.1) 4 21.1(6.1e45.6) 4 21.1(6.1e45.6)
Comp. 10 0.1(0.0e0.1) 6 0.1(0.0e0.1) 11 0.1(0.0e0.1) 65 0.4(0.3e0.5) 135 1.2(1.0e1.5) 295 3.3(2.9e3.6) 3004 13.1(12.7e13.5)
Nervous System
Epilepsy TSC 72 76.6(66.7e84.7) 43 72.9(59.7e83.6) 43 69.4(56.4e80.4) 34 66.7(52.1e79.2) 18 60.0(40.6e77.3) 14 73.7(48.8e90.9) 7 36.8(16.3e61.6)
Comp. 458 2.5(2.3e2.7) 314 3.8(3.4e4.2) 439 2.8(2.5e3.0) 451 3.1(2.8e3.3) 442 4.1(3.7e4.5) 318 3.5(3.1e3.9) 972 4.2(4.0e4.5)
Psychiatric
ADHDb TSC 7 7.4(3.1e14.7) 2 3.4(0.4e11.7) 0 e 0 e 1 3.3(0.1e17.2) 0 e 0 e
Comp. 192 1.0(0.9e1.2) 142 1.7(1.4e2.0) 39 0.2(0.2e0.3) 6 0.0(0.0e0.1) 3 0.0(0.0e0.1) 1 0.0(0.0e0.0) 5 0.0(0.0e0.0)
Autism Spectrum
Disorders
TSC 15 16.0(9.2e25.0) 13 22.0(12.3e34.7) 7 11.3(4.7e21.9) 1 2.0(0.1e10.5) 3 10.0(2.1e26.5) 2 10.5(1.3e33.1) 0 e
Comp. 181 1.0(0.8e1.1) 89 1.1(0.8e1.3) 25 0.2(0.1e0.2) 25 0.2(0.1e0.2) 6 0.1(0.0e0.1) 6 0.1(0.0e0.1) 4 0.0(0.0e0.0)
Bipolar Disorder TSC 0 e 1 1.7(0.0e9.1) 2 3.2(0.4e11.2) 0 e 0 e 0 e 0 e
Comp. 1 0.0(0.0e0.0) 10 0.1(0.0e0.2) 56 0.4(0.3e0.4) 71 0.5(0.4e0.6) 45 0.4(0.3e0.5) 35 0.4(0.3e0.5) 68 0.3(0.2e0.4)
Depression TSC 0 e 7 11.9(4.9e22.9) 13 21.0(11.7e33.2) 23 45.1(31.1e59.7) 8 26.7(12.3e45.9) 6 31.6(12.6e56.6) 8 42.1(20.3e66.5)
Comp. 69 0.4(0.3e0.5) 1215 14.6(13.8e15.4) 3311 21.0(20.3e21.6) 4025 27.3(26.6e28.0) 3718 34.3(33.4e35.2) 3378 37.3(36.3e38.3) 8517 37.1(36.5e37.8)
Learning/Intellectual
Disability
TSC 32 34.0(24.6e44.5) 23 39.0(26.6e52.6) 30 48.4(35.5e61.4) 19 37.3(24.1e51.9) 8 26.7(12.3e45.9) 9 47.4(24.5e71.1) 7 36.8(16.3e61.6)
Comp. 145 0.8(0.7e0.9) 155 1.9(1.6e2.2) 127 0.8(0.7e0.9) 92 0.6(0.5e0.8) 84 0.8(0.6e0.9) 73 0.8(0.6e1.0) 72 0.3(0.2e0.4)
Speech and Language
Disorders
TSC 10 10.6(5.2e18.7) 4 6.8(1.9e16.5) 5 8.1(2.7e17.8) 8 15.7(7.0e28.6) 6 20.0(7.7e38.6) 3 15.8(3.4e39.6) 1 5.3(0.1e26.0)
Comp. 409 2.2(2.0e2.4) 213 2.6(2.2e2.9) 96 0.6(0.5e0.7) 59 0.4(0.3e0.5) 67 0.6(0.5e0.8) 89 1.0(0.81.2) 326 1.4(1.3e1.6)
Kidney &Urinary
Tract
Kidney Neoplasms
(inc. Angiomyolipoma)
TSC 3 3.2(0.7e9.0) 6 10.2(3.8e20.8) 11 17.7(9.2e29.5) 9 17.6(8.4e30.9) 6 20.0(7.7e38.6) 4 21.1(6.1e45.6) 1 5.3(0.1e26.0)
Comp. 0 e 1 0.0(0.0e0.0) 1 0.0(0.0e0.0) 1 0.0(0.0e0.0) 1 0.0(0.0e0.0) 0 e 1 0.0(0.0e0.0)
Chronic Kidney
Disease
TSC 1 1.1(0.0e5.8) 1 1.7(0.0e9.1) 4 6.5(1.8e15.7) 4 7.8(2.2e18.9) 9 30.0(14.7e49.4) 6 31.6(12.6e56.6) 8 42.1(20.3e66.5)
Comp. 32 0.2(0.1e0.2) 30 0.4(0.2e0.5) 103 0.7(0.5e0.8) 204 1.4(1.2e1.6) 307 2.8(2.5e3.1) 599 6.6(6.1e7.1) 5363 23.4(22.8e23.9)
Kidney Cyst TSC 1 1.1(0.0e5.8) 3 5.1(1.1e14.2) 7 11.3(4.7e21.9) 3 5.9(1.2e16.2) 0 e 1 5.3(0.1e26.0) 1 5.3(0.1e26.0)
Comp. 4 0.0(0.0e0.0) 8 0.1(0.0e0.2) 8 0.1(0.0e0.1) 13 0.1(0.0e0.1) 23 0.2(0.1e0.3) 30 0.3(0.2e0.4) 242 1.1(0.9e1.2)
Polycystic Kidney
Disease
TSC 0 e 3 5.1(1.1e14.2) 5 8.1(2.7e17.8) 3 5.9(1.2e16.2) 0 e 1 5.3(0.1e26.0) 1 5.3(0.1e26.0)
Comp. 7 0.0(0.0e0.1) 1 0.0(0.0e0.0) 6 0.0(0.0e0.1) 8 0.1(0.0e0.1) 13 0.1(0.1e0.2) 9 0.1(0.0e0.2) 24 0.1(0.1e0.1)
Circulatory System
Cardiac Rhabdomyoma TSC 18 19.1(11.8e28.6) 4 6.8(1.9e16.5) 0 e 0 e 0 e 0 e 0 e
Comp. 0 e 0 e 0 e 1 0.0(0.0e0.0) 0 e 2 0.0(0.0e0.1) 2 0.0(0.0e0.0)
Myocardial Infarction/
Angina
TSC 0 e 0 e 0 e 0 e 0 e 2 10.5(1.3e33.1) 4 21.1(6.1e45.6)
Comp. 3 0.0(0.0e0.0) 5 0.1(0.0e0.1) 1 0.2(0.1e0.2) 106 0.7(0.6e0.9) 342 3.2(2.8e3.5) 796 8.8(8.2e9.4) 4749 20.7(20.2e21.2)
Cerebral/Cardiac
Aneurysm
TSC 1 1.1(0.0e5.8) 3 5.1(1.1e14.2) 0 e 9 0.1(0.0e0.1) 2 6.7(0.8e22.1) 0 e 1 5.3(0.1e26.0)
Comp. 0 e 0 e 6 0.0(0.0e0.1) 0 e 12 0.1(0.0e0.2) 29 0.3(0.2e0.4) 118 0.5(0.4e0.6)
Dermatological
Angiofibroma TSC 0 e 2 3.4(0.4e11.7) 4 6.5(1.8e15.7) 6 11.8(4.4e23.9) 1 3.3(0.1e17.2) 2 10.5(1.3e33.1) 0 e
Comp. 0 e 13 0.0(0.0e0.0) 3 0.0(0.0e0.0) 1 0.0(0.0e0.0) 3 0.0(0.0e0.1) 0 e 6 0.0(0.0e0.0)
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e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 2 9 6e3 0 8302language disorders, autism spectrum disorders, behavioural
disorders, ADHD and learning disability (Fig. 3). In contrast,
angiomyolipomas and other kidney neoplasms were diag-
nosed later in childhood (12.1 [6.6] years of age). Dermatolog-
ical conditions including benign skin neoplasms and
angiofibromas also first presented in childhood (14.5 [4.2] and
16.3 [1.8] years of age, respectively). On average, brain neo-
plasms (including SEGA) were first diagnosed at 9.4 (6.5) years
of age. Suspected cases of lymphangioleiomyomatosis (LAM)
were not present in the TSC Birth cohort. However, in the TSC
cohort, suspected LAM cases were identified at an average age
of 49.4 (26.2) years.
3.5. Clinical profiles of the TSC cohort
Further analyses were conducted to better understand the
combination of primary organ systems (as defined in MedI-
TOSC) affected in patients with TSC. Each distinct combina-
tion was considered a manifestation profile. A total of forty-
nine manifestation profiles were identified in the TSC
cohort, with 6% of patients having a unique manifestation
profile that was not observed in any other patient. In paedi-
atric and adult TSC cohorts, 46% and 62% of patients,
respectively, developed clinical manifestations in at least
three of the organ systems.
The collective organ system profile of the TSC cohort was
represented using a network diagram to illustrate the rela-
tionship between organ systems affected and overall disease
complexity (Fig. 4). A strong relationship between nervous
system, psychiatric and dermatological manifestations was
observed in the TSC cohort, partly reflecting a high preva-
lence of manifestations in each of these organ systems, but
also the inherent relationship between brain abnormalities
and psychopathology (Fig. 2). The relationship between res-
piratory, circulatory system and brain (structural) manifes-
tations was the least pronounced in the TSC cohort.
3.6. TSC cohort mortality
Data on mortality was examined to ascertain a potential
reason for comparatively lower proportion of adult TSC pa-
tients versus the Comparator cohort. Analysis of the ONS
mortality register showed that only 5% of the TSC cohort
(n ¼ 16) had died. These patients had amean (SD) age at death
of 57.5 (20.5) years (median, 61.1 years of age).4. Discussion
This study is a retrospective, longitudinal analysis of a large
cohort of TSC patients in the UK who were treated in general
practice. It represents one of the largest population-based
studies reporting on this condition. It contributes towards a
better understanding of the complexity of this disease and
the associated treatment challenges impacting the delivery
of patient care in the community setting. Comprehensive
data on known TSC manifestations are reported, including
their recorded prevalence, age of onset and the different
combinations in which they occur, providing further insight
into the broad spectrum of TSC clinical profiles.
Table 2B e Prevalence of additional clinical manifestations in the paediatric vs. adult TSC population.
TSC clinical manifestations <18 yrsa
n ¼ 94
18 yrsa
n ¼ 240
n % (95% CI) n % (95% CI)
Brain (Structural)
Hydrocephalus 3 3.2 (0.7e9.4) 13 5.4 (3.1e9.1)
Psychiatric
Sleep Disorder 12 12.8 (7.3e21.2) 29 12.1 (8.5e16.9)
Behavioural Disorder 17 18.1 (11.5e27.2) 34 14.2 (10.3e19.2)
Kidney & Urinary Tract
Haematuria 1 1.1 (0.0e6.4) 20 8.3 (5.4e12.6)
Circulatory System
Hypertension 0 e 25 10.4 (7.1e15.0)
Arrhythmia 3 3.2 (0.7e9.4) 12 5.0 (2.8e8.6)
Dermatological
Cafe au Lait Spots 3 3.2 (0.7e9.4) 0 e
Acne vulgaris/rosacea 1 1.1 (0.0e6.4) 32 13.3 (9.6e18.3)
Naevus 5 5.0 (2.0e12.0) 15 6.0 (4.0e10.0)
Nail Manifestations 5 5.3 (2.0e12.2) 45 18.8 (14.3e24.2)
Skin Tag 0 e 12 5.0 (2.8e8.6)
Respiratory System
Lymphangioleiomyomatosis (LAM)b 0 e 4 1.7 (0.5e4.4)
a Age defined at the point of the last available record for each patient.
b Suspected cases of LAM only due to unavailability of specific LAM diagnosis codes in CPRD-HES.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 2 9 6e3 0 8 303Manifestations that are less common in TSC patients,
including visual impairment and thyroid disease, have also
been described in this study.
The study reflects clinical practice over the time span of
the review. A number of complications were recorded at a
lower prevalence than one would expect based on small
expert research studies18,21; the difference is probably likely to
represent under-diagnosis, highlighting inadequate care.
A novel approach was taken in the study to categorise all
manifestations identified in the TSC cohort resulting in the
development of an inventory of clinical codes by organ sys-
tem, MedITOSC. The development of the inventory was a
critical first step in the study to support all subsequent ana-
lyses and has the potential to evolve over time asmore clinical
data on TSC patients becomes available and can be used to
support future TSC studies planned in the CPRD-HES
databases.
All patient records available in the CPRD-HES (~7 million)
were used to identify a diagnosis record for TSC. Based on an
estimated population prevalence of 1/20,000 of diagnosed
TSC,14,15,18 the expected number of patients in the CPRD-HES
was approximately 350 patients. The current study identified
334 TSC patients, which is consistent with the expected
number in the general CPRD-HES population. However,
additional reports have estimated the prevalence of TSC at 1/
11,000, taking into account undiagnosed cases.14 This sug-
gests that there are a similar number of TSC patients in the
CPRD-HES without a recorded diagnosis. The demographic
findings support this hypothesis but also raise questions
around a potentially higher impact of TSC on mortality than
previously documented.30 The TSC patient cohort had a
distribution of gender and available history that was
consistent with the Comparator cohort. However, the age
distribution of patients differed substantially betweencohorts, with a smaller proportion of older patients observed
in the TSC cohort versus the Comparator cohort (11% vs. 31%
of subjects over 55 years of age). This under-representation
of older adults in the CPRD-HES could reflect historical
under-diagnosis of TSC, older patients seeking care in
alternative facilities not captured in CPRD-HES, or a loss to
follow-up during the transition to adulthood due to a lack of
coordinated care.
This study reports the prevalence of TSC manifestations
and contrasts this against the prevalence in the general CPRD
population. The most common manifestations were derma-
tological and nervous system manifestations (predominantly
epilepsy). These were markedly more frequent than in the
Comparator cohort at all age intervals and concur with pre-
vious reports,31e34 although others have reported an even
higher prevalence of epilepsy (85%) in the setting of a
specialist TSC clinic.35 The prevalence of angiofibromas were
lower than expected.18,19 This could be due to misdiagnosis of
acne vulgaris or rosacea due to physicians lack of familiarity
with TSC and related dermatological manifestations in gen-
eral practice. A high occurrence of lymphoedemawas noted in
the 45e65 year age interval but no TSC patients were diag-
nosed outside of this age band. While an association has
previously been suggested,36 our data are not able to offer any
additional insights on this particular association. The
apparent increased prevalence of impetigo in adults with TSC
has not been described previously and is likely to be associ-
atedwith other TSC-related dermatologicalmanifestations, or
may result from poor hygiene and subsequent susceptibility
to infection.
As anticipated, the TSC cohort had a higher prevalence of
brain neoplasms (including SEGA) with 11% of paediatric TSC
patients affected compared with 0% in the Comparator
cohort. Epilepsy and brain neoplasms (including SEGA) are
Fig. 3 e A box plot showing the variation in age of TSC patients at first diagnosis record for select clinical manifestations
(n ≥ 5) by primary organ system. Analyses were conducted in the sub-population of TSC patients for whom records were
available from birth; TSC Birth cohort (n ¼ 124). NS, Nervous System; K & UT, Kidney and Urinary Tract; CS, Circulatory
System.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 2 9 6e3 0 8304known to pose a risk of serious neurological complications.37
Epilepsy has been strongly linked to learning/intellectual
disability,35,38,39 and has a detrimental impact on patient
quality of life40,41; consequently, epilepsy should be the
subject of vigilant surveillance in all patients with suspected
TSC. This agrees with our findings surrounding the combi-
nation of organ systems affected in the TSC cohort, which
demonstrated a strong relationship between nervous system
and psychiatric manifestations, with further association of
brain (structural) manifestations. Vigilant monitoring of pa-
tients will result in earlier detection of these manifestations,
allowing interventions to be administered sooner. In turn,
this will mitigate the risk of developing more severe com-
plications later in life, which are harder to treat and have a
higher clinical burden.
Psychiatric manifestations were seen in over half of pae-
diatric (55%) and adult (68%) TSC patients, consistent with
previous estimates (~40e80%).42 The high prevalence, which
increased with age, highlights the importance of psychiatric
referral and the need for a coordinated approach to improve
the quality and efficiency of care. Intellectual disability was
observed in over one-third of children with TSC (compared
with 1% in the general CPRD population). Similarly, autism
spectrum disorders (16%) and ADHD (7%) also develop more
frequently in paediatric TSC patients compared with the
Comparator cohort. However, prior research has typically re-
ported higher prevalence estimates for these conditions.43e45The lower prevalence in our TSC cohort might be explained
by under-reporting of these conditions in general practice as
they are not routinely sought, further highlighting the need
for more systematic psychiatric assessment in TSC.
The kidney and urinary tract are also commonly affected in
TSC, with angiomyolipomas and simple renal cysts devel-
oping with increasing prevalence over the course of the dis-
ease.38,46,47 Severe early onset of polycystic kidney disease has
been associated with contiguous TSC2 and PKD1 gene de-
letions.48 Our findings were consistent with these reports and
notably, the prevalence of CKD stage 3e5 observed in adult
TSC patients (30%e42%) over the age of 45 years wasmarkedly
higher than that reported in the Comparator cohort (3%e23%).
Also noteworthy was a higher occurrence of stroke/TIA
accompanying the increase in CKD stage 3e5 prevalence in
the TSC cohort. Stroke/TIA may have occurred as a direct
result of hypertension, known to develop in patients with
CKD.49 The high rates of CKD stage 3e5 are likely a conse-
quence of the late detection and poor management of earlier
angiomyolipomas and renal cysts and, thus, strongly supports
the current TSC clinical guidelines for diagnosis and surveil-
lance recommending regular assessment of renal func-
tion.18,21 Our data suggest that CKD stage 3e5 is a more
frequent complication of TSC than previously understood and
may contribute to substantial morbidity in adulthood.
The lungs of adults with TSC, particularly women, are
frequently affected by LAM, a cystic lung disease that is an
Fig. 4 e In order to demonstrate the broad spectrum of
manifestation profiles (TSC-related and TSC-associated) in
the TSC cohort, the number of primary organ systems
affected for each patient was explored and presented as a
network diagram (n ¼ 324). The relative size of each node
reflects the frequency of organ system involvement while
the width of each connecting line (between nodes) reflects
the frequency of patients that have manifestations
involving both these organ systems. The most common
manifestation profile observed was patients with nervous
system, skin and psychiatric manifestations (21%).
Theoretically, the number of possible different individual
presentations is 77 at organ system level. However, there
are still many different combinations of manifestations in
TSC. Note: 7 patients in the TSC cohort did not develop a
clinical manifestation within any of the seven primary
organ systems.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 2 9 6e3 0 8 305increasingly important cause of morbidity and death in adults
with TSC.50 The low prevalence of respiratory disease in our
TSC cohort is striking since screening studies have shown that
lung cysts are present in 27% of women at 21 years and 80% of
women at 40 years.51 LAM symptoms are frequently attributed
to more common diseases including asthma and COPD52 and
our data suggest that LAM may have been overlooked in our
cohort, with only ‘suspected’ cases of LAM identified. An early
diagnosis of LAM may prevent complications and disability53;
adoption of the recent TSC management guidelines, which
recommend screening adult women for LAM by computerised
tomography scanning, should improve recognition of LAM.21
Several manifestations were also observed in other organ
systems that are not well recognised as being affected by TSC,
including those in the endocrine and gastrointestinal
systems13,18e20
Manifestations reported in these particular organ systems
were higher compared with the Comparator cohort, providing
preliminary frequency data for these under-reported features
as well as suggesting that they may be TSC-related. Of note
was the higher prevalence of hypothyroidism/hyperthyroid-
ism in the TSC cohort when compared with the Comparator
cohort, especially later in adulthood. Only a few studies have
previously reported abnormalities of the thyroid gland in TSC
patients.27,54 Paediatric and adult TSC patients were also
shown to have developed visual impairment more frequentlythan in the Comparator cohort, another manifestation that
has been explored less often in TSC. Suchmanifestations may
be under-reported in real clinical practice due to psychiatric
complications (e.g. intellectual disability) affecting surveil-
lance and adequate care of patients as well as the ability to
effectively communicate their symptoms; hyperactive and/or
autistic features may also aggravate this problem. Previous
studies have reported that the development of retinal astro-
cytic hamartomas may rarely affect vision,55 while raised
intracranial pressure due to progressing SEGAs is a well rec-
ognised cause of visual loss in TSC.56 Retinal side effects
associated with vigabatrin use for the treatment of seizures
have also been reported.21
Whilst TSC is known to involve multiple organ systems,
most published studies analyse only a single organ system.
This study highlights the complexity of TSC by reporting the
collective organ system profile of the TSC cohort. Forty-nine
different manifestation profiles by primary organ system
were identified within the TSC cohort (meaning considerably
more clinical profiles exist at the individual manifestation
level), with approximately half of paediatric and adult TSC
patients having involvement of three or more organ systems.
Considering the seven nodes in the network diagram (Fig. 4)
gives a mathematical possibility of 77 (823,543) different
combinations of organ system manifestations. In practice,
this finding underlines the enormous phenotypic variety in
TSC that makes management so complex. This lends
considerable weight to the requirement for a holistic and
coordinated management approach in order to deliver effi-
cient and effective care for TSC patients throughout their
lifetime.
A strength of this study lies in the large cohort of TSC
patients derived from the CPRD-HES, for whom available
history, on average, spanned almost two decades and the
inclusion of a substantial proportion for whom data was
available from birth. A further strength was the capture of
data from both primary and secondary health care settings.
This has enabled a greater understanding of the develop-
ment of clinical manifestations over time (including those
less frequently associated with TSC) and has allowed dif-
ferences in the prevalence of manifestations in both paedi-
atric and adult patients to be examined. Furthermore,
comprehensive review of each TSC patient record by a
number of clinical experts (resulting in the development of
MedITOSC) has validated TSC and manifestation diagnoses
as well as contributing more broadly to interpretation.
Finally, the CPRD has been shown to cover a representative
sample of patients in the UK22,25 and thus, findings from this
source are believed to be generalisable to the national TSC
population, with the caveat that many complications are
likely to be under-diagnosed.
The shortcomings of this study are typical for retrospec-
tive database studies, where data are limited by the level of
detail and quality of information recorded. For example,
accident and emergency visits are only reported in the CPRD-
HES if they result in a subsequent admission into hospital.
Another example is that the lack of a specific code for com-
mon TSC manifestations (e.g. hypomelanotic lesions, retinal
hamartomas, cerebral tubers) means that these are either
not recorded or possibly misreported. Additionally, the
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 2 9 6e3 0 8306linkage of the CPRD and HES databases was only available for
part of the study period, suggesting that patients may have
experienced additional events and diagnoses in specialist
care that we were unable to report (especially in the outpa-
tient setting). The manifestations reported in this survey are
a mixture of clinical problems for which patients sought
medical advice and some chance findings, representative of
TSC care in a primary practice. Routine surveillance has
generally been non-systematic in the UK and most patients
are not followed-up in TSC clinics; this may partially explain
some differences in prevalence of non-symptomatic lesions
(e.g. renal angiomyolipomas) reported for this population
and smaller intensively studied groups of patients from
specialised TSC centres.33 The prevalence of some manifes-
tations is likely to be under-reported, particularly those that
normally develop later in life, considering the relatively
young age of the TSC cohort in the CPRD-HES, or for those
manifestations where specific diagnosis codes are unavai-
lable (e.g. LAM). In addition, it is likely that some patients
with TSC are not captured in the CPRD-HES due to under- or
misdiagnosis of this disease. Furthermore, the low mortality
in the TSC cohort is likely to be under-reported due to the
younger age of the study population. Lastly, this study does
not include information from the mental health and social
care settings and will, therefore, not capture all care
administered to TSC patients with psychiatric disorders.
This study has highlighted several areas that may warrant
further investigation. Firstly, given the under-representation
of adults in this particular TSC cohort, it would be beneficial
to explore the care pathways of adult TSC patients in the UK.
This would support a greater understanding of the health care
settings utilised by these patients, and identify both potential
points of sub-optimal care and those points at which patients
are lost to follow-up. Secondly, a study that aims to establish
the economic burden of TSC in the UK would provide addi-
tional insights in relation to the clinical findings reported for
the current study. Thirdly, considering the higher prevalence
of CKD stage 3e5 reported in our TSC cohort versus the gen-
eral CPRD population, future studies are required to delineate
the causes and effectiveness of treatment options for CKD in
TSC to prevent major morbidity. Finally, further studies to
confirm preliminary findings of greater occurrence of visual
impairment, thyroid disease, impetigo and lymphoedema in
TSC would also be of benefit.5. Conclusion
To the authors' knowledge, this represents one of the largest
TSC cohort studies undertaken in the general population
and highlights the substantial burden of this genetic disor-
der in the UK. The study demonstrates the complex nature
of TSC, with patients presenting with a broad spectrum of
manifestation profiles that evolve over time. Recent clinical
guidelines aimed at improving diagnosis, clinical surveil-
lance and management of TSC18,21 provide a benchmark
against which current practice and service provision can be
measured and support the need for a coordinated care
approach to improve long-term health outcomes for pa-
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